Work

Determinants of resistance to nivolumab (nivo) monotherapy investigated through genomic and transcriptomic analysis of renal cell carcinoma (RCC) tumors from the HCRN GU16-260 study.

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.16_suppl.4524

Authors: David A. Braun, Kelly Street, Opeyemi Jegede, Neil Ruthen, Miya Hugaboom, Nicholas R Schindler, David F. McDermott, Elizabeth R. Plimack, Jeffrey A. Sosman, Naomi B. Haas, Michael E. Hurwitz, Hans J. Hammers, Sabina Signoretti, Michael B. Atkins, Catherine J. Wu

Institutions: Yale University, University of Southern California, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Fox Chase Cancer Center, Northwestern University, Abramson Cancer Center, The University of Texas Southwestern Medical Center, Brigham and Women's Hospital

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4379332744

Cites:

Cited by:

Related to: 10